Shares in Angle, the Surrey-based technology investment firm, fell today after it reported delays to its IVF product EmbryoSure.
The embryo viability product is being developed by Novocellus, which is 82% owned by Angle.
The firm had already said the trial of EmbryoSure was delayed, but today added that the timeframe for completing the trials was "at present uncertain".
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Agnle would meet with Origio, the firm responisble for the trials, at the end of this month to review options for progressing the trials, it said.
"We continue to believe that EmbryoSure has the potential to make a major impact in the IVF market and it is important to us that we get the trials completed and the product in the market as quickly as possible," said chief executive Andrew Newland.
Angle's share price fell 6% after the announcement.
-
Best-performing funds and investment trusts in stocks and shares ISAs of all timeAs ISAs celebrate their 26th birthday, we reveal the best-performing funds and investment trusts since stocks and shares ISAs launched in April 1999, and how much they would be worth today
-
Dividends: Reliability in uncertain timesDividends have formed over half of the total return of the UK market over the last 20 years. Dividend strategies have been under-appreciated while investors have focused on US mega cap technology. Income strategies may have more appeal in a tougher investment climate
